Notable
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
Primary endpoint(s) modified
Also in this update: Primary completion pushed from Jul 15, 2027 to Dec 15, 2027; Enrollment reduced: 125 → 105 participants
Stelexis BioSciencesPhase 1 NCT06533761 Registry history of NCT06533761 on ClinicalTrials.gov (opens the registry)